| abstract |
The present invention provides vaccines and immunogenic compositions of dengue virus for administration to human subjects; the vaccine compositions of the present invention comprise recombinantly produced monomeric and / or dimeric forms of truncated glycoprotein from the dengue virus envelope which, when formulated together with a pharmaceutically acceptable adjuvant and vehicle, induce balanced tetravalent immune responses; In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4; The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised and immunosenescent individuals; Methods for inducing a protective immune response in a population of human patients are also provided herein, by administering the compositions described herein to patients. |